Regulatory aspects of herbals and biologicals Detailed Syllabus for Pharmaceutical Regulatory Affairs M.Pharm first year second sem is covered here. This gives the details about credits, number of hours and other details along with reference books for the course.
The detailed syllabus for Regulatory aspects of herbals and biologicals M.Pharm 2017-2018 (R17) first year second sem is as follows.
M.Pharm. I Year II Sem
Course Objective: This course is designed to impart fundamental knowledge on Regulatory Requirements, Licensing
and Registration, Regulation on Labelling of Biologics in India, USA and Europe It prepares the students to learn in detail on Regulatory Requirements for biologics, Vaccines and Blood Products
Course Outcome: Upon the completion of the course the student shall be able to :
- Know the regulatory Requirements for Biologics and Vaccines
- Understand the regulation for newly developed biologics and biosimilars
- Know the pre-clinical and clinical development considerations of biologics
- Understand the Regulatory Requirements of Blood and/or Its Components Including Blood Products and label requirements
UNIT I: India : Introduction, Applicable Regulations and Guidelines, Principles for Development of Similar Biologics, Data Requirements for Preclinical Studies, Data Requirements for Clinical Trial Application, Data Requirements for Market Authorization Application, Post-Market Data for Similar Biologics, Pharmacovigilance. GMP and GDP.
UNIT II : USA: Introduction to Biologics; biologics, biological and biosimilars, different biological products, difference between generic drug and biosimilars, laws, regulations and guidance on biologics/ biosimilars, development and approval of biologics and biosimilars (IND, PMA, BLA, NDA, 510(k), pre-clinical and clinical development considerations, advertising, labelling and packing of biologics.
UNIT III : European Union: Introduction to Biologics; directives, scientific guidelines and guidance related to biologics in EU, comparability/ biosimilarity assessment, Plasma master file, TSE/ BSE evaluation, development and regulatory approval of biologics (Investigational medicinal products and biosimilars), pre-clinical and clinical development considerations; stability, safety, advertising, labelling and packing of biologics in EU.
UNIT IV : Vaccine regulations in India, US and European Union: Clinical evaluation, Marketing authorisation, Registration or licensing, Quality assessment, Pharmacovigilance, Additional requirements Blood and Blood Products Regulations in India, US and European Union: Regulatory Requirements of Blood and/or Its Components Including Blood Products, Label Requirements, ISBT (International Society of Blood Transfusion) and IHN (International Haemovigilence Network)
UNIT V : Herbal Products: Quality, safety and legislation for herbal products in India, USA and European Union.
TEXT AND REFERENCE BOOKS:
- FDA Regulatory Affairs: A Guide for Prescription Drugs, Medical Devices, and Biologics, Douglas J. Pisano , David S. Mantus ; Informa ,2008
- Biological Drug Products: Development and Strategies; Wei Wang , Manmohan Singh ; wiley,2013
- Development of Vaccines: From Discovery to Clinical Testing; Manmohan Singh , Indresh K. Srivastava ;Wiley, 2011
- www.who.int/biologicals/en
- www.fda.gov/BiologicsBloodVaccines/GuidanceComplianceRegulatoryInformation/
- www.ihn-org.com
- www.isbtweb.org
- Guidelines on Similar Biologics: Regulatory Requirements for Marketing Authorization in India
- www.cdsco.nic.in
- www.ema.europa.eu › scientific guidelines › Biologicals
- www.fda.gov/biologicsbloodVaccines/GuidanceCompliance Regulatory Information (Biologics)
For all other M.Pharm 1st Year 2nd Sem syllabus go to JNTUH M.Pharm Pharmaceutical Regulatory Affairs 1st Year 2nd Sem Course Structure for (R17) Batch.
All details and yearly new syllabus will be updated here time to time. Subscribe, like us on facebook and follow us on google plus for all updates.
Do share with friends and in case of questions please feel free drop a comment.